Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Company achieves 18% revenue growth and raises gross margin guidance despite international headwinds and FESGO withdrawal.
Moby summary of KORU Medical Systems, Inc.'s Q2 2026 earnings call
MAHWAH, N.J., August 05, 2026--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full year 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.